Published in Arthritis Res Ther on October 04, 2012
Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis (2013) 1.07
Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther (2016) 0.82
Evaluating tablet computers as a survey tool in rural communities. J Rural Health (2014) 0.80
Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis. Int J Clin Rheumtol (2015) 0.75
Incidence and Management of Cardiovascular Risk Factors in Psoriatic Arthritis and Rheumatoid Arthritis: A Population-Based Study. Arthritis Care Res (Hoboken) (2016) 0.75
Association between small dense LDL and sub-clinical atherosclerosis in patients with psoriatic arthritis. Clin Rheumatol (2016) 0.75
The impact of concomitant diffuse idiopathic skeletal hyperostosis on the achievement of minimal disease activity in subjects with psoriatic arthritis. Rheumatol Int (2015) 0.75
Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation (2007) 11.95
Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum (2006) 10.39
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med (2010) 7.12
Psoriatic arthritis. Semin Arthritis Rheum (1973) 6.08
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum (2001) 5.87
Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation (2003) 4.52
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis (2011) 2.61
Changing concepts of atherogenesis. J Intern Med (2000) 2.23
Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation (2005) 2.03
Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol (2010) 1.93
Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol (2008) 1.70
Platelet reactivity and disease activity in subjects with psoriatic arthritis. J Rheumatol (2011) 1.51
Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis (2007) 1.46
Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis (2006) 1.39
Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J Gastroenterol (2010) 1.35
High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum (2007) 1.31
Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) (2010) 1.31
What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis (2007) 1.09
Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) (2011) 1.08
Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken) (2010) 1.06
Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) (2013) 1.05
The multiple facets of the fat tissue. Thyroid (2008) 1.04
Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol (2011) 1.02
Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. J Rheumatol (2012) 0.98
Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism. Thromb Res (2011) 0.95
Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers. J Rheumatol (2012) 0.91
Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost (2012) 0.86
Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis (2010) 0.82
Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study. Ann Rheum Dis (2009) 0.82
TNF-α blockers and carotid intima-media thickness: an emerging issue in the treatment of psoriatic arthritis. Intern Emerg Med (2011) 0.81
Psoriatic arthritis: pharmacoeconomic considerations. Curr Rheumatol Rep (2009) 0.79
Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum (2005) 2.39
Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol (2012) 2.18
Early psoriatic arthritis: the clinical spectrum. J Rheumatol (2007) 1.79
Mental status impairment in patients with West Haven grade zero hepatic encephalopathy: the role of HCV infection. J Gastroenterol (2007) 1.56
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol (2011) 1.52
Platelet reactivity and disease activity in subjects with psoriatic arthritis. J Rheumatol (2011) 1.51
Is the Nail Psoriasis Severity Index reliable in the assessment of nail psoriasis by rheumatologists? Arthritis Care Res (Hoboken) (2012) 1.46
"Obesity paradox" or "metabolically benign obesity"? Eat Weight Disord (2013) 1.39
Incidence of hypertension in individuals with different blood pressure salt-sensitivity: results of a 15-year follow-up study. J Hypertens (2007) 1.20
Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol (2006) 1.19
Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol (2009) 1.18
Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol (2012) 1.17
Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol (2004) 1.15
Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively? J Inflamm (Lond) (2009) 1.13
Differences of myocardial systolic deformation and correlates of diastolic function in competitive rowers and young hypertensives: a speckle-tracking echocardiography study. J Am Soc Echocardiogr (2010) 1.09
Treatment of hemophilia: a review of current advances and ongoing issues. J Blood Med (2010) 1.07
Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis (2013) 1.07
Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) (2013) 1.05
Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol (2011) 1.02
Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol (2011) 1.02
Bariatric surgery and diabetes remission: sleeve gastrectomy or mini-gastric bypass? World J Gastroenterol (2013) 1.00
Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol (2006) 1.00
Is there any consensus as to what diet or lifestyle approach is the right one for NAFLD patients? J Gastrointestin Liver Dis (2012) 1.00
What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J Gastroenterol (2013) 0.99
Hepatitis C virus lymphotropism and peculiar immunological phenotype: effects on natural history and antiviral therapy. World J Gastroenterol (2009) 0.98
The potential role of bone scintigraphy in the detection of deep muscular fascia involvement and calcinosis cutis in anti-synthetase syndrome. Int J Rheum Dis (2013) 0.98
Disseminated intravascular coagulation in hematologic malignancies. Semin Thromb Hemost (2010) 0.98
Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. J Rheumatol (2012) 0.98
Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol (2010) 0.97
Comorbid conditions in the AMICA study patients: effects on the quality of life and drug prescriptions by general practitioners and specialists. Semin Arthritis Rheum (2005) 0.97
Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford) (2012) 0.96
Have guidelines addressing physical activity been established in nonalcoholic fatty liver disease? World J Gastroenterol (2012) 0.96
Extensive psoriasis induced by pegylated interferon: a case report. J Med Case Rep (2007) 0.95
Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol (2014) 0.94
Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol (2013) 0.94
The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol (2007) 0.94
Clinical presentation of osteoarthritis in general practice: determinants of pain in Italian patients in the AMICA study. Semin Arthritis Rheum (2005) 0.92
Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers. J Rheumatol (2012) 0.91
Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. J Transl Med (2011) 0.91
Effects of treatment with metformin on TSH levels: a meta-analysis of literature studies. J Clin Endocrinol Metab (2013) 0.91
Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost (2011) 0.91
New developments in magnetic resonance imaging of the nail unit. J Rheumatol Suppl (2012) 0.91
Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life. Med Sci Monit (2011) 0.91
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery. Cochrane Database Syst Rev (2015) 0.90
Should visceral fat be reduced to increase longevity? Ageing Res Rev (2013) 0.90
Filling the gap between science & clinical practice: prevention of stroke recurrence. Thromb Res (2011) 0.90
Troponin I and right ventricular dysfunction for risk assessment in patients with nonmassive pulmonary embolism in the Emergency Department in combination with clinically based risk score. Intern Emerg Med (2008) 0.90
Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol (2011) 0.90
Tissue factor and atherosclerosis: not only vessel wall-derived TF, but also platelet-associated TF. Thromb Res (2011) 0.90
Computed tomography findings of pneumatosis and portomesenteric venous gas in acute bowel ischemia. World J Gastroenterol (2013) 0.89
Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathies. Arthritis Rheum (2005) 0.89
Homocysteine and arterial thrombosis: Challenge and opportunity. Thromb Haemost (2010) 0.89
Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study. Am J Hematol (2012) 0.89
Wernicke encephalopathy in subjects undergoing restrictive weight loss surgery: a systematic review of literature data. Eur Eat Disord Rev (2014) 0.88
Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies. Ann Med (2015) 0.88
High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. World J Gastroenterol (2010) 0.88
The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol (2014) 0.87
Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol (2013) 0.87